Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Xortx Gets Orphan Drug Nod for Polycystic Kidney Disease

Xortx Gets Orphan Drug Nod for Polycystic Kidney Disease
Xortx Therapeutics has received Orphan Drug designation for its Xorlo (oxypurinol) drug to treat autosomal dominant polycystic kidney disease, the most common form of polycystic kidney disease.

Xorlo inhibits the production of uric acid, a key to reducing injury to the kidney.

The company plans on speaking with the FDA on May 1 about its planned phase 3 clinical program of the drug candidate.

Orphan Drug designation offers incentives for companies such as a possible tax credit of 25 percent of qualified clinical drug testing costs upon drug approval.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX, dedicated to developing medications to improve the quality of life and future health of patients. Founded: 2011. Headquarters: Vancouver, Canada.

April 24, 2023

https://www.fdanews.com/
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies